BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer

Bristol Myers Squibb on Thursday released data from the Phase III CheckMate-8HW trial, demonstrating the first-line potential of its combination regimen involving Opdivo (nivolumab) and Yervoy (ipilimumab) in metastatic colorectal cancer.